Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

October 17, 2016

Primary Completion Date

October 2, 2018

Study Completion Date

April 8, 2019

Conditions
CirrhosisPortal HypertensionNon-alcoholic Steatohepatitis
Interventions
DRUG

Emricasan

DRUG

Placebo

Trial Locations (37)

19104

Philadelphia, Philadelphia

19141

Philadelphia, Philadelphia

20014

San Sebastian, Donostia / San Sebastian

21202

Baltimore, Baltimore

23226

Richmond, Richmond

23249

Richmond, Richmond

23502

Norfolk, Norfolk

27710

Durham, Durham

28006

Madrid, Madrid

28034

Madrid, Madrid

28046

Madrid, Madrid

28222

Majadahonda, Majadahonda

30309

Atlanta, Atlanta

33157

Palmetto Bay, Palmetto Bay

38138

Germantown, Germantown

39008

Santander, Santander

46010

Valencia, Valencia

46104

Valencia, Valencia

48149

Münster, Münster

48202

Detroit, Detroit

50325

Clive, Clive

53127

Bonn, Bonn

55114

Saint Paul, Saint Paul

55131

Mainz, Mainz

55905

Rochester, Rochester

64131

Kansas City, Kansas City

76012

Arlington, Arlington

77030

Houston, Houston

78215

San Antonio, San Antonio

78233

San Antonio, San Antonio

91105

Pasadena, Pasadena

92377

Rialto, Rialto

98104

Seattle, Washington, Seattle

06120

Halle (Saale), Halle

04103

Leipzig, Leipzig

08035

Barcelona, Barcelona

08036

Barcelona, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Histogen

INDUSTRY